Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.

Chengxin LiQianqian YuanTong DengGaoran XuJinxuan HouLewei ZhengGao-Song Wu

Published in: Breast cancer (Tokyo, Japan) (2023)

HER2-low BC patients have longer OS and DFS compared to HER2-zero BC patients, and its prognostic value is consistent among different HR status patients. Whether HER2-low breast cancer is an independent subtype of breast cancer is still a subject of ongoing research, and more studies are needed to fully understand the molecular and clinical features of this subtype.

Keyphrases

end stage renal disease
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported